Government widens probes of antipsychotic Risperdal

Johnson & Johnson has acknowledged that government probes into the sales and marketing of its antipsychotic drug Risperdal have been expanding. Risperdal was J&J's biggest seller last year, bringing in $3.55 billion. Investigators have been demanding internal corporate documents, including records of payments to doctors.

- read this Wall Street Journal report (sub. req.)